MAPT and Alzheimer disease: Given the limited success of AD treatments focused on targeting Aβ plaques or Tau tangles, modulating mitochondrial Ca2+ levels by targeting influx and efflux pathways (e.g., MCU, NCLX, or LETM1) presents a promising alternative approach that warrants further investigation.